Shenzhen Hepalink Pharmaceutical Group Valuation
Is 9989 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9989 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9989 (HK$4) is trading below our estimate of fair value (HK$121.25)
Significantly Below Fair Value: 9989 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9989?
Key metric: As 9989 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 9989's PS Ratio? | |
|---|---|
| PS Ratio | 2.9x |
| Sales | CN¥5.45b |
| Market Cap | CN¥14.45b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.9x |
| Enterprise Value/EBITDA | 59x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 9989's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
867 China Medical System Holdings | 2.4x | 14.7% | HK$18.1b |
512 Grand Pharmaceutical Group | 1.4x | 6.2% | HK$15.1b |
570 China Traditional Chinese Medicine Holdings | 0.6x | 4.8% | HK$11.0b |
2096 Simcere Pharmaceutical Group | 2.4x | 12.1% | HK$16.4b |
9989 Shenzhen Hepalink Pharmaceutical Group | 2.9x | 5.5% | HK$14.5b |
Price-To-Sales vs Peers: 9989 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the peer average (1.7x).
Price to Sales Ratio vs Industry
How does 9989's PS Ratio compare vs other companies in the HK Pharmaceuticals Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
3320 China Resources Pharmaceutical Group | 0.1x | 8.0% | US$4.19b |
8329 Shenzhen Neptunus Interlong Bio-technique | 0.2x | n/a | US$29.33m |
1312 Kontafarma China Holdings | 0.2x | n/a | US$21.55m |
| 3 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 9989 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the Hong Kong Pharmaceuticals industry average (1.4x).
Price to Sales Ratio vs Fair Ratio
What is 9989's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.9x |
| Fair PS Ratio | 1.8x |
Price-To-Sales vs Fair Ratio: 9989 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.34
7D
0.7%
1Y
n/a
3SBio
HK$13.1b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.55
7D
-2.5%
1Y
-25.1%
JW (Cayman) Therapeutics
HK$534.0m
A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.
2126
HK$1.32
7D
-0.8%
1Y
-51.1%